Orthovita Rhakoss
This article was originally published in The Gray Sheet
Executive Summary
Orthopedic biomaterials manufacturer plans to file for a CE mark by year end, following completed enrollment of 70 cervical spinal fusion patients in a nine-site pivotal trial. Patients will be followed for six months. The synthetic bone spinal implant is a potentially safer alternative to allograft for cervical spinal fusion surgery, Orthovita contends (1"The Gray Sheet" Aug. 26, 2002, p. 28)...
You may also be interested in...
Rhakoss Spinal Implant May Be Safer Alternative To Allograft – Orthovita
Orthovita is emphasizing its Rhakoss synthetic bone spinal implant as a potentially safer alternative to allograft for cervical spinal fusion surgery
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.